Haemophilus influenzae type B (HIB)
Follow the links below to find trusted information about haemophilus influenzae type B (HIB).
Last reviewed: July 2016
Need more information?
These trusted information partners have more on this topic.
Found 82 results
Haemophilus influenzae type B (Hib)
Haemophilus influenzae type B (Hib) is a bacterium commonly found in the upper respiratory tract (windpipe, back of mouth and nose).
Read more on WA Health website
Immunise - Haemophilus influenzae type B (Hib)
Haemophilus influenzae type B (Hib) Page last updated: 20 April 2015 Haemophilus influenzae type B (Hib) is a bacterium commonly found in the upper respiratory tract, which can cause a range of serious diseases particularly in young children
Read more on Department of Health website
Haemophilus Influenzae Type b (Hib) Disease
Infection with Hib bacteria can lead to serious illness including meningitis and epiglottitis. With the introduction of Hib vaccine these conditions are now rare. Urgent treatment is necessary as Hib disease can be life threatening.
Read more on NSW Health website
Haemophilus influenzae type b (Hib) | Public Health
Read more on Tasmanian Department of Health and Human Services website
Haemophilus influenzae - myDr.com.au
The bacterium Haemophilus influenzae type b (Hib) can cause meningitis and epiglottitis. Since routine Hib vaccination started in Australia, the number of cases of Hib infection has been greatly reduced.
Read more on myDr website
Haemophilus influenzae type b - Aboriginal and Torres Strait Islander peoples Australian Indigenous HealthInfoNet
These web pages provide information and resources about the burden of Haemophilus influenza type B (Hib) infection within Aboriginal and Torres Strait Islander communities.
Read more on Australian Indigenous HealthInfoNet website
Immunise - National Immunisation Program Schedule (From November 2016)
National Immunisation Program Schedule (From November 2016) Page last updated: 25 November 2016 PDF printable version of the National Immunisation Program Schedule - PDF 113 KB Child programs Age Vaccine Birth Hepatitis B (hepB)a 2 months Hepatitis B, diphtheria, tetanus, acellular pertussis (whooping cough), Haemophilus influenzae type b, inactivated poliomyelitis (polio) (hepB-DTPa-Hib-IPV) Pneumococcal conjugate (13vPCV) Rotavirus 4 months Hepatitis B, diphtheria, tetanus, acellular pertussis (whooping cough), Haemophilus influenzae type b, inactivated poliomyelitis (polio) (hepB-DTPa-Hib-IPV) Pneumococcal conjugate (13vPCV) Rotavirus 6 months Hepatitis B, diphtheria, tetanus, acellular pertussis (whooping cough), Haemophilus influenzae type b, inactivated poliomyelitis (polio) (hepB-DTPa-Hib-IPV) Pneumococcal conjugate (13vPCV) Rotavirus b 12 months Haemophilus influenzae type b and meningococcal C (Hib-MenC) Measles, mumps and rubella (MMR) 18 months Diphtheria, tetanus, acellular pertussis (whooping cough) Measles, mumps, rubella and varicella (chickenpox) (MMRV) 4 years Diphtheria, tetanus, acellular pertussis (whooping cough) and inactivated poliomyelitis (polio) (DTPa-IPV) School programs Age Vaccine 1015 years (contact your State or Territory Health Department for details) Varicella (chickenpox) c Human papillomavirus (HPV) d Diphtheria, tetanus and acellular pertussis (whooping cough) (dTpa) At-risk groups Aboriginal and Torres Strait Islanders Age Vaccine 1218 months (In high risk areas) e Pneumococcal conjugate (13vPCV) 1224 months (In high risk areas) f Hepatitis A 6 months to less than 5 years Influenza (flu) 15 years and over Influenza (flu) Pneumococcal polysaccharide (23vPPV) (medically at risk) 50 years and over Pneumococcal polysaccharide (23vPPV) Other at-risk groups Age Vaccine 6 months and over (people with medical conditions placing them at risk of serious complications of influenza) Influenza (flu) 12 months (medically at risk) e Pneumococcal conjugate (13vPCV) 4 years (medically at risk)e Pneumococcal polysaccharide (23vPPV) Pregnant women (at any stage of pregnancy) Influenza (flu) 65 years and over Influenza (flu) Pneumococcal polysaccharide (23vPPV) 70 years (a free single catch-up dose is available for adults aged 71-79 years until 31 October 2021) Herpes Zoster (Shingles) Footnotes to the National Immunisation Program (NIP) Schedule Hepatitis B: vaccine should be given to all infants as soon as practicable after birth
Read more on Department of Health website
Immunise - Hepatitis B
Hepatitis B Page last updated: 20 April 2015 Hepatitis B is a potentially life threatening liver infection caused by the hepatitis B virus
Read more on Department of Health website
Immunise - Influenza (Flu)
Influenza (Flu) Page last updated: 12 March 2017 Influenza (flu) is a highly contagious viral infection that spreads easily from person to person through coughing, sneezing and close contact
Read more on Department of Health website
Immunise - Diseases and Programs A-Z
Information about the diseases that are vaccinated against under the Immunise Australia Program.
Read more on Department of Health website
Found 9 results
Vaccines for preventing severe Haemophilus influenzae type b (Hib) infections in people with sickle cell disease | Cochrane
Vaccines for preventing severe Haemophilus influenzae type b (Hib) infections in people with sickle cell disease
Read more on Cochrane (Australasian Centre) website
Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines in healthy infants up to two years old | Cochrane
Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines in healthy infants up to two years old
Read more on Cochrane (Australasian Centre) website
Haemophilus influenzae type B and viral influenza vaccinations during pregnancy for improving maternal, neonatal and infant health outcomes | Cochrane
Haemophilus influenzae type B and viral influenza vaccinations during pregnancy for improving maternal, neonatal and infant health outcomes
Read more on Cochrane (Australasian Centre) website
Hepatitis B vaccination during pregnancy for preventing infant infection | Cochrane
Hepatitis B is an infection caused by the hepatitis B virus and occurs worldwide. For infants and children, the two main sources of the infection are transmission from an infected mother or living in an infected household. Perinatal transmission is common in highly endemic areas. Hepatitis B vaccines are available and require a series of three doses over six months. The most common side effects are pain at the vaccination site and mild to moderate fever. Maternal hepatitis B vaccine immunization may be a way of preventing hepatitis B infection in infants before hepatitis B vaccine can be administered and provide protection to the infant. Infected hepatitis B virus infants are more likely to develop complications such as chronic infection, cirrhosis or liver cancer (hepatocellular carcinoma). This review found no evidence from randomized controlled trials regarding the effects of hepatitis B vaccine for preventing infant infection.
Read more on Cochrane (Australasian Centre) website
Vaccines for preventing influenza in people with cystic fibrosis | Cochrane
People with cystic fibrosis have blocked airways which results in frequent airway infections. Infections with viral diseases like influenza ("the flu") can worsen lung damage. Doctors therefore often advise people with cystic fibrosis to be vaccinated against influenza every year. We searched for studies which compared different vaccines or compared vaccination to placebo. We were able to include four studies with 179 people in the review. Most (143) were under 16 years old. No study compared one vaccine to placebo. There were a high number of drop outs in two of the studies. Vaccination does result in an immune system response to the types of influenza used in the vaccine. However, this response may not result in protection against influenza infection or lung damage. There were a high number of adverse events, but none were serious or persistent. There is no evidence to show if regular influenza vaccine benefits people with cystic fibrosis.
Read more on Cochrane (Australasian Centre) website
Vaccines for preventing severe salmonella infections in people with sickle cell disease | Cochrane
Salmonella organisms are probably second only to pneumococcus among bacterial causes of infection in people with sickle cell disease. Infection with these bacteria can lead to complications and reduce the quality of life of people with the disease and sometimes result in death. Immunization with salmonella vaccines is one of the interventions available to reduce infection by these bacteria. There are different types of vaccines available: the inactivated vaccines and the oral vaccines. We did not find any randomized controlled trials assessing these vaccines in people with sickle cell diseases. We therefore conclude that there is a need for a randomized controlled trial to assess the benefits and risks of the different types of vaccines to evaluate the potential for improving survival and decreasing mortality from salmonella infections in people with sickle cell disease.
Read more on Cochrane (Australasian Centre) website
Pneumococcal vaccines for sickle cell disease | Cochrane
People with sickle cell disease are particularly prone to pneumococcal infection, which may be fatal. Children aged up to 23 months are at high risk, but usual polysaccharide pneumococcal vaccines may not work in this age group. New conjugate pneumococcal vaccines may help to reduce the rate of infection in people with sickle cell disease of all ages. We searched for trials which compared a polysaccharide or conjugate pneumococcal vaccine schedule with a different schedule or no vaccination in people with sickle cell disease. The review includes five trials with a total of 547 participants. One trial showed that the polysaccharide vaccine did not reduce the risk of infection very much in children younger than three years old, but it was linked with only minor adverse events. Three trials of conjugate vaccines showed increased antibody responses compared to control groups in people of all ages, although clinical outcomes were not measured in these trials. This review did not show if the vaccines prevent infection or decrease death rates. We recommend that conjugate pneumococcal vaccines are used in people with sickle cell disease. Randomised trials will be needed to determine the best vaccination schedule when further, potentially more effective vaccines become available. Such trials should measure clinical outcomes of effectiveness.
Read more on Cochrane (Australasian Centre) website
Needle size for vaccination procedures in children and adolescents | Cochrane
Vaccines contain antigens that make our immune system produce antibodies that can protect against disease. Antigens are modified or partial forms of the virus, bacteria, or the toxin that cause the disease that the vaccine protects against. Because the antigen is altered from its original form it cannot cause disease, but it can produce an immune response.
Read more on Cochrane (Australasian Centre) website
Review of respiratory disease among Indigenous peoples Reviews Respiratory health (LungInfoNet) Chronic conditions Australian Indigenous HealthInfoNet
/uploads/docs/respiratory-review.pdf
Read more on Australian Indigenous HealthInfoNet website
